Toshio Kubo

机构：Okayama University Hospital · ORCID：0000-0002-2545-3052

发表论文 262 篇 · 总被引 4049 次 · h-index 31

代表论文

Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial (2024 · EClinicalMedicine · 被引 34)
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC (2025 · Journal of Thoracic Oncology · 被引 27)
A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence (2023 · JAMA Oncology · 被引 19)
Trastuzumab deruxtecan (T-DXd) in patients with HER2 -mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. (2024 · Journal of Clinical Oncology · 被引 10)
Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022 (2024 · International Journal of Clinical Oncology · 被引 7)
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022 (2024 · International Journal of Clinical Oncology · 被引 6)